Starpharma Holdings Limited (AU:SPL) has released an update.
Starpharma Holdings Limited showcased the final results of their DEP irinotecan Phase 1/2 clinical trial at the American Society of Clinical Oncology 2024 Annual Meeting, a notable achievement given the competitive selection process for presentations. The company’s dendrimer-based drug delivery technology for cancer treatments drew significant attention from global oncology professionals. Publication in the Journal of Clinical Oncology further underscores the trial’s positive findings for cancer patient care.
For further insights into AU:SPL stock, check out TipRanks’ Stock Analysis page.
